News Releases

Date	Title	View
March 11, 2024	Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference	PDF Version
March 9, 2024	Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting	PDF Version
March 6, 2024	Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction	PDF Version
March 4, 2024	Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting	PDF Version
March 1, 2024	Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS	PDF Version